Genetic Variants Associated with Gefitinib Adverse Events in Non-Small Cell Lung Cancer: A Systematic Review Integrated with Protein-Protein Interaction Network and Structural Modelling
DOI:
https://doi.org/10.53366/jimki.vi.v12i2.1049Keywords:
Gefitinib, Non-Small Cell Lung Cancer, adverse effectAbstract
Introduction: Lung cancer remains the leading cause of cancer-related death worldwide, with non–small cell lung cancer (NSCLC) accounting for approximately 85% of cases. Gefitinib is a tyrosine kinase inhibitor frequently used in NSCLC with favorable outcome. However, many patients develop severe adverse effects which might be influenced by genetic variability. Therefore, we aim to systematically review the gene variants and its association with gefitinib-related adverse effects in NSCLC patients, as well as investigate the biological process involved.
Methods: A systematic search was conducted according to PRISMA guidelines across PubMed, Scopus, and Cochrane. Studies investigating the association between genetic variations with gefitinib-related adverse effects in NSCLC were included. Risk of bias was assessed using the Cochrane RoB-E. Extracted data encompassed study and patient characteristics, adverse effects, and gene variations. Significant genes identified from included studies were analyzed through PPI network analysis, and the hub proteins found were visualized through Chimera.
Results: Sixteen studies involving 1,176 patients were included, with Japanese populations being the most studied. Gene variants of CYP2D6, CYP3A4, ABCB1, ABCG2, EGFR, FOXO3, IKBKB, and AKT1 were found to be associated with adverse effects such as hepatotoxicity, skin rash, and diarrhea among NSCLC patients. Metabolism and inflammatory pathways might be involved in gefitinib-related adverse effects.
Conclusion: Genetic variations in CYP2D6, CYP3A4, ABCB1, ABCG2, EGFR, FOXO3, IKBKB, and AKT1 may influence gefitinib-associated adverse effects, highlighting the need of pharmacogenomic testing to guide personalized treatment and improved patient safety.
Keywords: Genetic Variants, Gefitinib, Non-Small Cell Lung Cancer, Adverse Effects, Protein-protein interaction
References
1. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA, Clin M, et al. Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship [Internet]. Vol. 83, Mayo Clin Proc. 2008. Available from: www.mayoclinicproceedings.com.
2. Midha A, Dearden S, Mccormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII) [Internet]. Vol. 5, Am J Cancer Res. 2015. Available from: www.ajcr.us/
3. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma. New England Journal of Medicine. 2009 Sep 3;361(10):947–57.
4. Lacouture M, Sibaud V. Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails. Vol. 19, American Journal of Clinical Dermatology. Springer International Publishing; 2018. p. 31–9.
5. Morau MV, Seguin CS, Perroud Junior MW, Dagli-Hernandez C, Pincinato E de C, Moriel P. Gefitinib-Induced Severe Dermatological Adverse Reactions: A Case Report and Pharmacogenetic Profile. Pharmaceuticals. 2024 Aug 1;17(8).
6. Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, et al. Severe acute interstitial pneumonia and gefitinib. Lancet. 2003 Jan 11;361(9352):137–9.
7. Roden DM, Wilke RA, Kroemer HK, Stein CM. Pharmacogenomics: The genetics of variable drug responses. Circulation. 2011 Apr 19;123(15):1661–70.
8. Guan S, Chen X, Chen Y, Wan G, Su Q, Liang H, et al. FOXO3 mutation predicting gefitinib-induced hepatotoxicity in NSCLC patients through regulation of autophagy. Acta Pharm Sin B. 2022 Sep 1;12(9):3639–49.
9. Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, Verweij J, et al. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst. 2006 Dec 6;98(23):1739–42.
10. Ma Y, Xin S, Huang M, Yang Y, Zhu C, Zhao H, et al. Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): A pharmacogenomic study of metabolic enzymes and transporters. Pharmacogenomics Journal. 2017 Jul 1;17(4):325–30.
11. Suzumura T, Kimura T, Kudoh S, Umekawa K, Nagata M, Matsuura K, et al. Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer. BMC Cancer. 2012 Dec 4;12.
12. Huang CL, Yang CH, Yeh KH, Hu FC, Chen KY, Shih JY, et al. EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment. Lung Cancer. 2009 Jun;64(3):346–51.
13. Lemos C, Giovannetti E, Zucali PA, Assaraf YG, Scheffer GL, Van Der Straaten T, et al. Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. Pharmacogenomics. 2011 Feb;12(2):159–70.
14. Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May 1;111(5):1007–21.
15. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Vol. 372, BMJ. BMJ Publishing Group; 2021.
16. Kwok WC, Lam DCL, Ip MSM, Tam TCC, Ho JCM. Association of genetic polymorphisms of CYP3A4 and CYP2D6 with gefitinib-induced toxicities. Anticancer Drugs. 2022 Nov 1;33(10):1139–44.
17. Shenoy P V., Baburaj G, Damerla RR, Pai A, Mailankody S, Munisamy M, et al. Influence of genetic polymorphisms on gefitinib pharmacokinetics and adverse drug reactions in non-small cell lung cancer patients. Vol. 44, Cancer metastasis reviews. 2025. p. 82.
18. Higgins JPT, Morgan RL, Rooney AA, Taylor KW, Thayer KA, Silva RA, et al. A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E). Environ Int. 2024 Apr 1;186.
19. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019 Jan 8;47(D1):D607–13.
20. Kobayashi H, Sato K, Niioka T, Miura H, Ito H, Miura M. Relationship among gefitinib exposure, polymorphisms of its metabolizing enzymes and transporters, and side effects in Japanese patients with non-small-cell lung cancer. Clin Lung Cancer. 2015 Jul 1;16(4):274–81.
21. Takimoto T, Kijima T, Otani Y, Nonen S, Namba Y, Mori M, et al. Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity. Clin Lung Cancer. 2013 Sep;14(5):502–7.
22. Sugiyama E, Umemura S, Nomura S, Kirita K, Matsumoto S, Yoh K, et al. Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations. Lung Cancer. 2015 Nov 1;90(2):307–13.
23. Tamura M, Kondo M, Horio M, Ando M, Saito H, Yamamoto M, et al. GENETIC POLYMORPHISMS OF THE ADENOSINE TRIPHOSPHATE-BINDING CASSETTE TRANSPORTERS (ABCG2, ABCB1) AND GEFITINIB TOXICITY. Vol. 74, Nagoya J. Med. Sci. 2012.
24. Akasaka K, Kaburagi T, Yasuda S, Ohmori K, Abe K, Sagara H, et al. Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer. Cancer Chemother Pharmacol. 2010 Sep;66(4):691–8.
25. Giovannetti E, Zucali PA, Peters GJ, Cortesi F, D’Incecco A, Smit EF, et al. Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib. Mol Cancer Ther. 2010 Mar;9(3):581–93.
26. Liu G, Gurubhagavatula S, Zhou W, Wang Z, Yeap BY, Asomaning K, et al. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics Journal. 2008 Apr;8(2):129–38.
27. Xin S, Zhao Y, Wang C, Huang Y, Zhuang W, Ma Y, et al. Polymorphisms of NF-κB pathway genes influence adverse drug reactions of gefitinib in NSCLC patients. Pharmacogenomics Journal. 2020 Apr 1;20(2):285–93.
28. Ruan Y, Jiang J, Guo L, Li Y, Huang H, Shen L, et al. Genetic Association of Curative and Adverse Reactions to Tyrosine Kinase Inhibitors in Chinese advanced Non-Small Cell Lung Cancer patients. Sci Rep. 2016 Mar 18;6.
29. Wu JM, Flynn JF, Wong C. Anti-EGFR therapy: Mechanism and advances in clinical efficacy in breast cancer. J Oncol. 2009;
30. Hirose T, Fujita K ichi, Kusumoto S, Oki Y, Murata Y, Sugiyama T, et al. Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer. Lung Cancer. 2016 Mar 1;93:69–76.
31. da Rocha Zurchimitten G, Camerini da Rosa L, Izídio G, Ghisleni G. Identifying genetic variants associated with side effects of antidepressant treatment: A systematic review. Prog Neuropsychopharmacol Biol Psychiatry. 2024 Jan 10;136:111154.
32. Zobdeh F, Eremenko II, Akan MA, Tarasov V V., Chubarev VN, Schiöth HB, et al. Pharmacogenetics and Pain Treatment with a Focus on Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Antidepressants: A Systematic Review. Pharmaceutics. 2022 Jun 1;14(6).
33. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. In: Nature Reviews Cancer. 2006. p. 803–12.
34. Takeda M, Nakagawa K. Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors in patients with epidermal growth factor receptor gene mutation-positive lung cancer. Mol Clin Oncol. 2017 Jan;6(1):3–6.
35. Cho S, Yee J, Kim JY, Jeong Rhie S, Gwak HS. Effects of Concomitant Medication Use on Gefitinib-Induced Hepatotoxicity. J Clin Pharmacol. 2018 Feb 1;58(2):263–8.
36. Park YH, Cho S, Yee J, Kim JY, Rhie SJ, Gwak HS. Factors affecting time to reach and recover from gefitinib-induced hepatotoxicity. Anticancer Drugs. 2018;29(5):471–6.
37. Lipton JH, Brümmendorf TH, Gambacorti-Passerini C, Garcia-Gutiérrez V, Deininger MW, Cortes JE. Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option. Vol. 56, Blood Reviews. Churchill Livingstone; 2022.
38. Shyam Sunder S, Sharma UC, Pokharel S. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Vol. 8, Signal Transduction and Targeted Therapy. Springer Nature; 2023.
39. Hohenegger M. Pharmacokinetic considerations in geriatric cancer patients. Vol. 14, Memo - Magazine of European Medical Oncology. Springer; 2021. p. 11–4.
40. Teh LK, Bertilsson L. Pharmacogenomics of CYP2D6: Molecular genetics, interethnic differences and clinical importance. Vol. 27, Drug Metabolism and Pharmacokinetics. Japanese Society for the Study of Xenobiotics; 2012. p. 55–67.
41. Itoda M, Saito Y, Shirao K, Minami H, Ohtsu A, Yoshida T, et al. Eight Novel Single Nucleotide Polymorphisms in ABCG2 /BCRP in Japanese Cancer Patients Administered Irinotacan. Drug Metab Pharmacokinet. 2003 Feb 1;18(3):212–7.
Additional Files
Published
Issue
Section
License
Copyright (c) 2025 Agya Marsaa Rangga Pradipa, Muhammad Shalahudin Al Ayyubi, Sabila Romadhona, Widya Khairunnisa Sarkowi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.